Multiple Sclerosis "Whole-Brain" Disease Multiple Research Paper

PAGES
8
WORDS
2355
Cite

These include housing, access to work, education, training and leisure, transition planning for younger disabled people and local action for the stigma of mental health problems (Department of Health p 8). National Multiple Sclerosis Society

NMSS was organized in 1946 by those who want to do something about MS now (NMSS, 2010). They work together towards a world free of MS through a 50-state network of chapters. They do this by funding worthwhile research, initiating change through advocacy, facilitating professional education and providing programs and services for people with MS and their families so they can move forward. to-date, NMSS has extended vital support and personalized services to more than 350,000 people with MS, their families, friends and colleagues. In 2008 alone, it has spent $136 million for programs and 440 research projects around the world. Programs include customized local programming assistance through its network, quality of life programming family weekends and children's camps, scholarship support, information support program. More than 21 million web visits each year are received online, through telephone and in person (NMSS).

Thousands of individual volunteers across the country serve as community leaders, ambassadors and champions who support the Movement (NMSS, 2010). Funds for its programs come from corporate partners, such as BP, FedEx and corporations. The Bike MS and Walk MS events have been growing and attract more than $125 million each year. Individuals donate more than $50 million by direct marketing and online donations. Corporations donate kind an direct financial contributions. The Movement aims at raising $1.25 billion by the end of this year (NMSS).

Interventions and Recommendations

Anti-inflammatory Effects of Polyunsaturated Fatty Acids or PUFAs

Epidemiological studies suggest that saturated fat intake can lead to MS (Mehta et al.,

2009 p 82). On the other hand, the intake of PUFAs can inhibit inflammatory effects through multiple, complex mechanisms. Omega-3 and Omega-6 PUFAs p;ay a role in metabolic, immunologic, coagulation and inflammatory processes. They can be obtained from plant sources, such as sunflower, safflower, corn, wheat germ and soybean oils, and from fish oils. Several clinical trials with different results generally suggest the beneficial effect of PUFAs on MS. Their use should be further studied as a promising supplement to treatment or approach for MS through much larger and longer-term confirmatory trials than tried earlier (Mehta et al. 83-92). The use of PUFAs is highly recommended for their promised relief from the effects of MS. Further research on their benefits is also greatly encouraged.

Stem Cell Treatment

The use of stem cells may be a new way to address the management of MS and other neurodegenerative and neuroimmunological disorders (Karussis & Kassis, 2007 p 1201).

This is done by directing the migration of stem cells into the affected inflammatory areas to induce local immunomodulation and neuroprotection. Neuroprotection will accelerate or enhance the remyelinating mechanisms through the activation, growth and production of resident stem cells. The trans-differentiation...

...

Fusion mechanisms may occur instead of trans-differentiation but they may still be beneficial in inducing the rejuvenation of partially damaged CNS cells (Karussis & Kassis pp1190-1195).
Adult stem cells are most appropriate for human use as they incur less dangers and more responsive to ethical standards (Karussis & Kassis, 2007 p 1200-1201). The best compromise seems to be bone marrow-derived mesenchuman stem cells for the said purposes and for ease of use. These cells can induce strong peripheral immunomodulating effects if directly administered into the cerebrospinal fluid for best advantage (Karussis & Kassis pp 1196-1201). Stem cell therapy is recommended when warranted by sufficient controlled clinical trials in MS.

Multiple sclerosis or MS is a most afflicting and challenging condition. The unknown origin, the lack of exact cure and the suffering caused by MS on people justify massive attention and action of all kinds. #

BIBLIOGRAPHY

Borazanci, a.P., et al. (2009). Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology, 4 (2): Future Medicine, Ltd.

Retrieved on May 27, 2010 from http://www.medscape.com/viewarticle/589380

Department of Health (2010). Putting people first: a shared vision and commitment to the transformation of adult social care. UK: HM Government. Retrieved on May 27, 2010 from http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/odh/@en/documents/digitalasset/dh_081119.pdf

Gee, J. et al. (2005). The association of brainstem lesions with migraine-like headache:

an imaging study of multiple sclerosis. Headache, 45 (6): Blackwell Publishing.

Retrieved on May 28, 2010 from http://www.medscape.com/viewarticle/507375

Karussis, D. And Kassis, I. (2007). Use of stem cells for treatment of multiple sclerosis.

Expert Review of Neurotherapeutics: Future Drugs Ltd. Retrieved on May 27,

2010 from http://www.medscape.com/viewarticle/563024

Litzinger, M.J. J and Litzinger, M. (2009). Multiple sclerosis: a therapeutic overview.

US Pharmacist: Jobson Publishing. Retrieved on May 27, 2010 from http://www.medscape.com/viewarticle/588913

Mehta, L.R. et al. (2009). Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nature Clinic Practice Neurology: Nature Publishing

Group. Retrieved on May 27, 2010 from http://www.medscape.com/viewarticle/589464

MSAA (2010). About MSAA. Multiple Sclerosis Association of America. Retrieved on May 27, 2010 from http://www.msassociation.org/programs

Newland, P. (2009). Pain in women with relapsing-remitting multiple sclerosis and in health women: a comparative study. The Journal of Neuroscience Nursing, 40 (5):

American Association of Neuroscience Nurses. Retrieved on May 28, 2010 from http://www.medscape.com/viewarticle/582569

NMSS (2010). 2008 annual report. National Multiple Sclerosis Society. Retrieved on May 27, 2010 from http://www.nationalmsssociety.org/about_the_society/annual-report

Sources Used in Documents:

BIBLIOGRAPHY

Borazanci, a.P., et al. (2009). Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. Future Neurology, 4 (2): Future Medicine, Ltd.

Retrieved on May 27, 2010 from http://www.medscape.com/viewarticle/589380

Department of Health (2010). Putting people first: a shared vision and commitment to the transformation of adult social care. UK: HM Government. Retrieved on May 27, 2010 from http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/odh/@en/documents/digitalasset/dh_081119.pdf

Gee, J. et al. (2005). The association of brainstem lesions with migraine-like headache:
Retrieved on May 28, 2010 from http://www.medscape.com/viewarticle/507375
2010 from http://www.medscape.com/viewarticle/563024
US Pharmacist: Jobson Publishing. Retrieved on May 27, 2010 from http://www.medscape.com/viewarticle/588913
Group. Retrieved on May 27, 2010 from http://www.medscape.com/viewarticle/589464
MSAA (2010). About MSAA. Multiple Sclerosis Association of America. Retrieved on May 27, 2010 from http://www.msassociation.org/programs
American Association of Neuroscience Nurses. Retrieved on May 28, 2010 from http://www.medscape.com/viewarticle/582569
NMSS (2010). 2008 annual report. National Multiple Sclerosis Society. Retrieved on May 27, 2010 from http://www.nationalmsssociety.org/about_the_society/annual-report


Cite this Document:

"Multiple Sclerosis Whole-Brain Disease Multiple" (2010, May 29) Retrieved April 20, 2024, from
https://www.paperdue.com/essay/multiple-sclerosis-whole-brain-disease-10682

"Multiple Sclerosis Whole-Brain Disease Multiple" 29 May 2010. Web.20 April. 2024. <
https://www.paperdue.com/essay/multiple-sclerosis-whole-brain-disease-10682>

"Multiple Sclerosis Whole-Brain Disease Multiple", 29 May 2010, Accessed.20 April. 2024,
https://www.paperdue.com/essay/multiple-sclerosis-whole-brain-disease-10682

Related Documents

Embryonic Stem Cells to Cure Disease Embryonic Stem Cell Derivation of Human Embryonic Stem Cells Generation of Cardiomyocytes from Human Embryonic Stem Cells Purified Population of Cardiomyocytes Use of Transgenes in Differentiated Cardiomyocytes Use of Human Embryonic Stem Cells for Heart Conditions Neurological Disorders and Use of Human Embryonic Stem Cells Parkinson's Disease Stroke Huntington's disease Amyotrophic Lateral Sclerosis Human Embryonic Stem Cells for the Generation of Functional Hepatic Cells Ethical Considerations of Using Human Embryonic Stem Cells Social Oppression Value of the Embryo Pluripotent

Marijuana is one of the most discussed drugs in the world because of arguments based on its benefits and perceived detrimental effects. Part of the reason for the arguments is that marijuana is still classified federally as a Schedule 1 narcotic, meaning it falls under the class of hard drugs—such as heroin, LSD and cocaine (DEA, 2018). Thus, many countries limit its use and sale. However, many people actually see

Abstract Alzheimer’s disease is a type of dementia, while Parkinson’s disease is known as a debilitating neurodegenerative disease that affects significantly more men than women. The two disorders have some similar symptoms but are also very different. With regards to treatment, no standard intervention has been developed for the treatment of Alzheimer’s disorder. The only existing drugs are those that address some of the symptoms. Likewise, there is no standard therapy

Phase II consists of efficacy trials of the drug, which are tested on volunteers of the target population. When everything goes right, the drug manufacturer discusses the development process, continued human testing, other concerns and protocols for phase III with the FDA. Phase III is the more extensive. It is at this time that the manufacture can work for the accelerated development and review of the drug. Treatment IND

In Germany it is still an offence under the drug laws to posses the drug but the laws are some what more liberal. For example the prosecution may not press charges where the drug was found to be in 'low quantity 'and was for personal use. Thus patients have received lower penalties. The progress in Germany is such that in April 2000, the German company THC Pharm received the

(World Bank, 2007) Modern approaches to plant cloning or tissue culture techniques have been utilized by various nurseries in Thailand and the U.S. To bring rare and new species of plants in the commercial market, sometimes even before the botanists can manage to give the species a name. (Ogden, 2007) Tissue engineered products have a bright marketing potential since they provide better alternatives to other forms of treatments. Cartilage and